Patient Care

With COVID-19 limiting resources and presenting logistical challenges for elective treatments, Weill Cornell Medicine and NewYork-Presbyterian clinicians offer guidance on treating cancer in three recently published papers.

As the epicenter of the COVID-19 pandemic moves to Latin America and Africa, Weill Cornell Medicine faculty based in Haiti, a country hard hit by natural disasters and poverty, have developed lessons on what low-resourced countries can do to address and treat the outbreak on the ground.

When COVID-19 first appeared in NYC hospitals, Weill Cornell Medicine and NewYork-Presbyterian physicians and scientists documented early observations of clinical and pathological characteristics in two publications.

In randomized clinical trials, commercial sponsorship influences how studies are designed and the results reported in ways that often benefit the study’s sponsor, Weill Cornell Medicine and NewYork-Presbyterian investigators report.

A drug that blocks a male hormone receptor prolonged life by nearly a year compared with the placebo in men with nonmetastatic, castration-resistant prostate cancer, according to the final analysis of the results of an international, multi-center Phase 3 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Dr. Monika Safford, chief of the Division of General Internal Medicine at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, finds that obesity is linked to more serious complications from COVID-19, including in younger people.

As doctors face the novel coronavirus that causes COVID-19 with a very limited arsenal of treatments, physicians at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to test candidate drugs in clinical trials.

Although COVID-19 is a threat to everyone, people of color have been hit especially hard by the virus — what has been called a “pandemic within the pandemic.”

With the goal of advancing the fight against COVID-19, the Partners of Citadel and Citadel Securities have made a $2 million gift to Weill Cornell Medicine to develop new approaches to protect people from the disease and identify new cases of it.

Our Q&A video series provides information and advice from experts in different areas of medicine

As hospitals and emergency departments urge more patients to stay home to avoid exposing themselves and others to COVID-19 and to reduce stress on the healthcare system, patient care has increasingly moved to web-based video and audio technology called telemedicine.

A joint report released today by Dr. Steven Spandorfer of Weill Cornell Medicine and Sital Kalantry of Cornell Law School examines the medical and legal elements of gestational surrogacy.

For most of the American public, the immediate health risk from the new coronavirus, which causes COVID-19, is considered low. 

The short-term risk of a second stroke following an initial minor stroke is roughly 60 percent higher for black patients compared with white patients, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian researchers.

When professional musician Rik Albani was diagnosed with an aortic aneurysm and a leaky valve, he worried that he may not be able to play the trumpet again. 

When I sit in the doctor’s office, I wonder what she thinks of me.

Apps, video games and other media are filling gaps in mental healthcare

Weill Cornell Medicine scientists have built the first global database of clinical trials testing a rapidly expanding approach to cancer treatment that involves genetically modifying immune cells to recognize specific targets on a patient’s cancer cells and attack them.

African American patients who underwent knee-replacement surgery were several times more likely than white patients of similar age to be discharged to inpatient facilities for post-operative care and rehabilitation rather than home, according to a large study from a team led by Weill Cornell Medicine investigators. 

Weill Cornell Medicine and the University of Virginia School of Medicine have received a grant from the National Heart, Lung, and Blood Institute and Three Lakes Partners, a philanthropic family organization, to fund the first precision medicine research initiative aiming to transform the diagnosis and treatment of interstitial lung diseases, particularly idiopathic pulmonary fibrosis.